‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

Kallyope chooses obesity, IBD for its first two gut-restricted small molecule programs

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule programs into the clinic to treat obesity and inflammatory bowel disease.

All of

Read the full 470 word article

How to gain access

Continue reading with a
two-week free trial.